Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Lumos Pharma, Inc. clinical trials
Also known as NewLink Genetics.
Part of Double Point Ventures LLC, which holds 100% as of 2024-12-12. Source
The registry lists 42 studies whose lead sponsor is Lumos Pharma, Inc.. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 19, 2026.
Keep track of what changes. Save the Lumos Pharma, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Lumos Pharma, Inc..
- NewLink Genetics Corporation34 studiesSame company
Something wrong?
- Lumos Pharma8 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 42 of 42.
- Phase 3 Study of LUM-201 in Children With Growth Hormone DeficiencyRecruitingNCT06948214Phase 3
Sponsor listed in the registry: Lumos Pharma
- Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese AdultsNot yet recruitingNCT07754045Phase 2
Sponsor listed in the registry: Lumos Pharma
- Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain CancerNot yet recruitingNCT07732413Phase 1
Sponsor listed in the registry: Lumos Pharma
- Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone DeficiencyNot yet recruitingNCT07129759Phase 3
Sponsor listed in the registry: Lumos Pharma
- A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)Enrolling by invitationNCT05796440Phase 2
Sponsor listed in the registry: Lumos Pharma
- A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerTerminatedNCT02389985Phase 1/2
Sponsor listed in the registry: NewLink Genetics Corporation
- Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)CompletedNCT04614337Phase 2
Sponsor listed in the registry: Lumos Pharma
- Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic MelanomaCompletedNCT02073123Phase 1/2
Sponsor listed in the registry: NewLink Genetics Corporation
- Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)CompletedNCT05250063Phase 2
Sponsor listed in the registry: Lumos Pharma
- Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic CancerCompletedNCT02077881Phase 1/2
Sponsor listed in the registry: NewLink Genetics Corporation
- Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain TumorsCompletedNCT02052648Phase 1/2
Sponsor listed in the registry: NewLink Genetics Corporation
- PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212)Active, not recruitingNCT04806854Phase 2
Sponsor listed in the registry: Lumos Pharma
- Immunotherapy Study for Patients With Stage IV MelanomaTerminatedNCT02054520Phase 2
Sponsor listed in the registry: NewLink Genetics Corporation
- A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic MelanomaTerminatedNCT03301636Phase 2
Sponsor listed in the registry: NewLink Genetics Corporation
- Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) ImmunotherapyTerminatedNCT03165188
Sponsor listed in the registry: NewLink Genetics Corporation
- Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung CancerTerminatedNCT02460367Phase 1
Sponsor listed in the registry: NewLink Genetics Corporation
- Immunotherapy Study for Metastatic Renal Cell CancerCompletedNCT02035358Phase 1
Sponsor listed in the registry: NewLink Genetics Corporation
- Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.WithdrawnNCT00753740Phase 2
Sponsor listed in the registry: NewLink Genetics Corporation
- Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid TumorsTerminatedNCT02380677Phase 1/2
Sponsor listed in the registry: NewLink Genetics Corporation
- A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02835729Phase 1
Sponsor listed in the registry: NewLink Genetics Corporation
- NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid TumorsCompletedNCT03164603Phase 1
Sponsor listed in the registry: NewLink Genetics Corporation
- Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain TumorsCompletedNCT02502708Phase 1
Sponsor listed in the registry: NewLink Genetics Corporation
- Vaccine Treatment for Advanced Breast CancerTerminatedNCT00090480Phase 1/2
Sponsor listed in the registry: NewLink Genetics Corporation
- Vaccine Treatment for Surgically Resected Pancreatic CancerCompletedNCT00255827Phase 1/2
Sponsor listed in the registry: NewLink Genetics Corporation
- Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast CancerCompletedNCT01792050Phase 2
Sponsor listed in the registry: NewLink Genetics Corporation
- Low Dose Vaccine Study for Surgically Resected Pancreatic CancerTerminatedNCT00614601Phase 2
Sponsor listed in the registry: NewLink Genetics Corporation
- Oral Bioavailability,and Food Effect Study and Single Ascending Dose PK Study in Healthy Male VolunteersCompletedNCT03372239Phase 1
Sponsor listed in the registry: NewLink Genetics Corporation
- Immunotherapy Study for Surgically Resected Pancreatic CancerCompletedNCT01072981Phase 3
Sponsor listed in the registry: NewLink Genetics Corporation
- A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung CancerCompletedNCT01380769Phase 2
Sponsor listed in the registry: NewLink Genetics Corporation
- Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male VolunteersCompletedNCT03852446Early Phase 1
Sponsor listed in the registry: NewLink Genetics Corporation
- Vaccine Treatment for Advanced Malignant MelanomaCompletedNCT00300612Phase 1/2
Sponsor listed in the registry: NewLink Genetics Corporation
- Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic CancerTerminatedNCT01836432Phase 3
Sponsor listed in the registry: NewLink Genetics Corporation
- Vaccine Maintenance Treatment for Non-Small Cell Lung CancerTerminatedNCT00420732Phase 2
Sponsor listed in the registry: NewLink Genetics Corporation
- Study of CRLX101 (NLG207) in the Treatment of Advanced Solid TumorsCompletedNCT00333502Phase 1/2
Sponsor listed in the registry: NewLink Genetics Corporation
- CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)CompletedNCT02187302Phase 2
Sponsor listed in the registry: NewLink Genetics Corporation
- IDO Inhibitor Study for Relapsed or Refractory Solid TumorsTerminatedNCT00739609Phase 1
Sponsor listed in the registry: NewLink Genetics Corporation
- Vaccine Study for Surgically Resected Pancreatic CancerCompletedNCT00569387Phase 2
Sponsor listed in the registry: NewLink Genetics Corporation
- Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid TumorsTerminatedNCT02648711Phase 1
Sponsor listed in the registry: NewLink Genetics Corporation
- Immunotherapy and SBRT Study in Borderline Resectable Pancreatic CancerTerminatedNCT02405585Phase 2
Sponsor listed in the registry: NewLink Genetics Corporation
- Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung CancerTerminatedNCT01774578Phase 2/3
Sponsor listed in the registry: NewLink Genetics Corporation
- Vaccine Treatment for Advanced Non-Small Cell Lung CancerCompletedNCT00073398Phase 1/2
Sponsor listed in the registry: NewLink Genetics Corporation
- Vaccine Treatment for Hormone Refractory Prostate CancerCompletedNCT00105053Phase 1/2
Sponsor listed in the registry: NewLink Genetics Corporation